M&A / Deals Merck KGaA and Remepy join forces to develop combo drug-digital therapies Pharmaceutical TechnologyMerck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication.Read full story pharminent April 28, 2026 (Last updated: April 29, 2026) Pharmaceutical Technology Merck KGaA and Remepy will work in tandem to develop drug-digital therapy combinations for a rare cancer indication. Read full story Post navigation Previous: Novartis shares fall as Entresto sales weakenNext: GSK eyes October FDA verdict on chronic hep B drug Related Stories M&A / Deals BioMarin spends up to $490m for Alesta’s bone disease candidate pharminent August 19, 2026 M&A / Deals J&J hands lymphoma bispecific CAR T back to AbelZeta pharminent August 17, 2026 M&A / Deals Novo Nordisk and AWS form AI partnership to speed drug discovery pharminent August 17, 2026
